April 26, 2019 07:02 AM EDTUpdated 10:06 AM
R&D

Cel­e­brat­ing sus­tained sales growth, As­traZeneca qui­et­ly ex­e­cutes some ag­ing mid-stage drug projects

John Carroll

Editor & Founder

While As­traZeneca ex­ecs clus­tered by the front door to dis­cuss their third straight quar­ter with ris­ing sales dri­ven by new can­cer drugs and an ex­pand­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times